AMCP supports increased access to Prescription Digital Therapeutics (PDTs). PDTs are software-based therapies that deliver clinical benefits to patients, either alone or in combination with other forms of treatment. These therapeutics require a prescription and are subject to oversight by the Food and Drug Administration (FDA). To be approved by the FDA, PDTs must demonstrate both safety and efficacy.
AMCP recognizes that many patients today depend on high‐cost specialty medications that often do not have therapeutic alternatives. Medication cost-share offset programs provide out-of-pocket discounts or free product at the point of sale.
The rebate system is an important lever for ensuring the affordability of prescription medications and health care premiums for Americans. AMCP supports the use of a rebate system as one of many levers to help to control drug costs.
Where We Stand: Use of appropriate medication regimens, regardless of cost, may help to improve patients’ conditions, improve quality of life, and lower other health care costs.
Where We Stand: AMCP urges policymakers and stakeholders to reject the criminalization of medication dispensing in favor of rigorous scientific standards used to determine the safest and most effective care for patients.